by The Nausea Medicine Market is estimated to be valued at US$ 7.52 Bn or Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Nausea medicines are drugs that are prescribed to relieve nausea and vomiting. They work by blocking signals in the brain that cause nausea or by reducing motion sickness. Common nausea medicines include antiemetics such as prochlorperazine, metoclopramide, ondansetron, granisetron, and scopolamine patch. They are available in oral tablet, capsule, syrup, and patch forms. Nausea medicines find wide applications in treating nausea associated with pregnancy, chemotherapy, motion sickness, gastroenteritis, food poisoning, anesthesia and pain medications among others.
Market Dynamics:
Rising prevalence of nausea-causing conditions is a key factor driving the nausea medicine market. For instance, according to the American Society of Clinical Oncology, in 2021, nearly 1.9 million new cases of cancer were diagnosed. Moreover, nearly two-thirds of people undergoing chemotherapy suffer from nausea and vomiting. This is creating a surge in demand for antiemetic drugs globally. Additionally, increasing incidences of conditions that may cause nausea including gastroenteritis, morning sickness during pregnancy and migraine is expected to further push the demand for nausea medications over the forecast period.
However, side effects associated with antiemetic drugs including drowsiness, constipation and extrapyramidal effects are limiting their demand to some extent. To counter this, companies are engaged in developing safer and more efficacious antiemetic drugs which can widen their applications and help expand the market. For instance, recent introduction of selective 5-HT3 receptor antagonists and neurokinin-1 (NK-1) receptor antagonists have enabled better control of chemotherapy-induced nausea and vomiting along with relatively fewer side effects.
Segment Analysis
The nausea medicine market is dominated by over-the-counter (OTC) anti-nausea drugs, which accounted for over 60% revenue share in 2023. Easy availability, lesser consultation requirements and growing self-medication practices have increased the demand for OTC drugs for minor nausea issues. Prescription anti-emetics is the next major segment and is expected to witness strong growth led by increasing incidence of cancer-related nausea and demand for advanced antiemetic drugs.
PEST Analysis
Political: Regulations related to drug development, drug approval and pricing influence market dynamics. Favorable regulatory conditions promote new product launches.
Economic: Rising healthcare spending across major countries and growing disposable incomes support market growth. However, pricing pressures impact sales of certain products.
Social: Increasing incidence of lifestyle diseases, cancer and growing social acceptance of self-medication are key drivers. Social media also influences health-related purchasing decisions.
Technological: Advancements in drug delivery systems, development of novel molecules and combination therapies enhance treatment effectiveness and market opportunities.
Key Takeaways
Global Nausea Medicine Market Demand is expected to witness high growth, exhibiting CAGR of 5.9% over the forecast period, due to increasing incidence of cancer, gastrointestinal disorders and motion sickness.
On a regional basis, North America dominates the nausea medicine market and is expected to continue its dominance over the forecast period. This is attributed to the presence of advanced healthcare facilities and growing cancer prevalence in the region. Asia Pacific is anticipated to witness the fastest growth over 2023-2030 backed by rising healthcare spending, expansion of healthcare systems and increasing awareness about nausea treatments.
Key players operating in the nausea medicine market are GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Eli Lilly and Company. These players are focused on developing advanced drug formulations and combination therapies to effectively manage various types of nausea.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
